Tel Aviv, Israel

The trials here

What the trial at this site is about, from its registry record.

Conditions

• Diabetic eye disease

Running trials

• Active, not recruiting

  A Study to Evaluate the Efficacy and Safety of 2 Doses of Remigromig (EYE103) Compared With Ranibizumab (0.5 mg) in Participants With DME

  NCT06571045· Phase 2/3· EyeBiotech Ltd.· Source